(Q40963307)

25 September 2017

1 reference

title

The role of chemotherapy in the treatment of multiple myeloma (English)

1 reference

25 September 2017

Bergsagel DE

1

1 reference

25 September 2017

1 December 1995

1 reference

Best Practice and Research: Clinical Haematology

25 September 2017

1 reference

25 September 2017

8

1 reference

25 September 2017

783-794

1 reference

25 September 2017

4

1 reference

Simultaneous occurrence of myelomonocytic leukemia and multiple myeloma: involvement of common leukemic progenitors and their developmental abnormality of "lineage infidelity".

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

High-dose glucocorticoid treatment of resistant myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Treatment of Plasma Cell Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Use a gentle approach for refractory myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Management of refractory myeloma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables--diagnostic and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Magnetic resonance imaging in the staging of solitary plasmacytoma of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980259-8

7 January 2021

10.1016/S0950-3536(05)80259-8

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8845572